◈ Nootpedia
Compact view
Research pass: medium Compound NOT-RELEVANT HIGH

Venlafaxine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict NOT-RELEVANT HIGH

No indication for Dylan. Notorious withdrawal syndrome (worst of the SNRIs). Effective drug for severe MDD/GAD but high discontinuation burden + side-effect profile not justified absent diagnosis.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    NOT-RELEVANT
  • 30-50, executive maintenance
    NOT-RELEVANT

    unless severe MDD.

  • 50+, mild cognitive decline
    NOT-RELEVANT

    for cognition; caution re: BP elevation.

  • Anxiety-prone
    OPTIONAL-ADD

    only after SSRI failure. Discontinuation difficulty makes it a "high commitment" choice.

  • High athletic load, tested status
    SKIP-FOR-NOW

    BP elevation + cardiovascular load problematic; same drive/libido concerns.

  • Sleep-disordered
    SKIP-FOR-NOW

    activating, REM-suppressing.

  • Recovery-focused
    NOT-RELEVANT
  • Strength/anabolic-focused
    SKIP-PERMANENT
▸ Subjective experience (deep)

Activating, often increases BP/HR. Same SSRI emotional blunting + sexual dysfunction. Discontinuation: brain zaps (electrical sensations in head), severe dizziness, nausea, irritability, "flu-like" feel — can last weeks.

▸ Tolerance + cycling deep dive
  • Tolerance: Generally maintained.
  • Not cycled.
▸ Stacking deep dive

Avoid stacking with

  • MAOIs (serotonin syndrome, hypertensive crisis).
  • Tramadol, MDMA, 5-HTP.
  • Other sympathomimetics (stimulants OK clinically but BP additive).
▸ Drug interactions deep dive

Mild CYP2D6 substrate; negligible CYP inhibition. Cleaner interaction profile than fluoxetine/paroxetine.

▸ Pharmacogenomics

CYP2D6 PMs have ↑ parent + ↓ active metabolite ratio; clinical impact modest.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Rx Pharmacy $8-25/mo generic XR high Generic available.
▸ Biomarkers to track (deep)
  • Baseline: PHQ-9, GAD-7, BP, HR, sodium, lipids.
  • During use: BP/HR every visit; PHQ-9 q4-6 weeks; sodium at 2 + 8 weeks.
  • Post-discontinuation: Withdrawal symptom diary if tapering.
▸ Controversies / open debates Live debate
  • Withdrawal severity: Widely acknowledged clinically; pharmacology of why (short half-life ~5h parent + active metabolite) explains pattern. Patient advocacy groups push for slower tapering than typical guidelines.
  • Effect size at high vs low dose: STAR*D and others suggest dose-response benefit; counter-arguments that this reflects placebo washout in non-responders.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: NOT-RELEVANT.
▸ Open questions / gaps Open

Whether desvenlafaxine (Pristiq) — the active metabolite as standalone — has meaningfully better tolerability and similar efficacy. Real-world withdrawal incidence likely underreported.

▸ Sources (full, with our context)
Back to compact view